Astrana Health (ASTH) Fundamental Analysis: Revenue, Earnings & Valuation

8.52 / 10

Outperform

Fundamentally, ASTH is rated Outperform with an 8.5/10 score. Revenue‑to‑market and cash metrics are bullish, driving strong cash flow growth. However, inventory turnover and sharply negative EPS YoY growth pose risks, tempering the otherwise robust outlook.

Analysis Checks(5/10)

Revenue-MV

Value1.61

Score2/3

Weight27.71%

1M Return3.89%

Net cash flow from operating activities per share (YoY growth rate %)

Value115.25

Score3/3

Weight34.07%

1M Return5.07%

Inventory turnover ratio

Value106.57

Score1/3

Weight10.23%

1M Return1.74%

Net income-Revenue

Value-2.84

Score0/3

Weight-12.33%

1M Return-2.25%

Basic earnings per share (YoY growth rate %)

Value-49.45

Score0/3

Weight-4.29%

1M Return-0.88%

Total profit (YoY growth rate %)

Value-50.99

Score0/3

Weight-12.09%

1M Return-2.61%

Net cash flow from operating activities (YoY growth rate %)

Value119.54

Score3/3

Weight37.47%

1M Return5.49%

Cash-UP

Value-0.16

Score2/3

Weight6.92%

1M Return0.89%

Diluted earnings per share (YoY growth rate %)

Value-48.89

Score0/3

Weight-4.48%

1M Return-0.92%

Cash-MV

Value0.03

Score2/3

Weight16.79%

1M Return2.77%

Is ASTH undervalued or overvalued?

ASTH scores 8.52/10 on fundamentals and holds a Discounted valuation at present. Backed by its 4.19% ROE, 0.76% net margin, 53.39 P/E ratio, 2.15 P/B ratio, and -49.45% earnings growth, these metrics solidify its Outperform investment rating.